What is the GLP-1 Drug Index?
The GLP-1 Drug Index is a reference list of every GLP-1-based medicine for weight loss that is approved or in late-stage trials, maintained by Peptide Analysis. For each drug it shows the maker, mechanism, how it is taken, its regulatory status and its main trial result. It was last updated on 10 November 2026.
How many GLP-1 drugs are FDA-approved for weight loss?
Six GLP-1-based products are FDA-approved for weight management: Semaglutide 2.4 mg, Semaglutide 7.2 mg, Oral semaglutide 25 mg, Orforglipron, Liraglutide 3.0 mg and Tirzepatide. Mazdutide is approved in China only, and three more (Retatrutide, Survodutide and CagriSema) are under FDA review or have finished Phase 3.
Which GLP-1 drugs come as a pill?
Two approved GLP-1 medicines are taken by mouth: Oral semaglutide 25 mg and Orforglipron. Oral versions of VK2735 and Amycretin are also in development.
What is the difference between GLP-1, dual and triple agonists?
A GLP-1 agonist such as semaglutide acts on one gut hormone receptor. Dual agonists add a second target: tirzepatide adds GIP, while mazdutide and survodutide add glucagon. Retatrutide is a triple agonist that acts on GLP-1, GIP and glucagon. Adding targets has generally produced more weight loss, sometimes with more side effects.
Who makes GLP-1 drugs?
Most GLP-1 medicines come from two companies: six in this index are from Novo Nordisk and four involve Eli Lilly. Others are developed by Amgen, Boehringer Ingelheim with Zealand Pharma, Innovent and Viking Therapeutics.
Where can I see GLP-1 drugs ranked?
This index is a reference list and does not rank drugs. To see them ranked, the GLP-1 Performance Index scores each medicine on how much weight it takes off for each unit of side effects.